LONG-TERM OUTCOMES OF DEEP BRAIN STIMULATION IN PATIENTS WITH PARKINSON'S DISEASE

Deep Brain Stimulation (DBS) has established itself over the past two decades as an effective method for comprehensive treatment of Parkinson's disease when conservative therapy proves ineffective or insufficiently effective. The method is based on the implantation of electrodes into specific brain structures (predominantly the subthalamic nucleus, globus pallidus, or ventral intermediate nucleus of the thalamus) with subsequent activation through a subcutaneously implanted neurostimulator. Electrical stimulation modulates pathological neuronal activity in the basal ganglia, which leads to a reduction in the main motor symptoms of the disease and allows for a significant decrease in the dosage of antiparkinsonian medications.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-04-29
DOI
https://doi.org/10.5281/zenodo.15301353
Primary Topic
Neurological disorders and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

LONG-TERM OUTCOMES OF DEEP BRAIN STIMULATION IN PATIENTS WITH PARKINSON'S DISEASE

Zenodo (CERN European Organization for Nuclear Research)
Neurological disorders and treatments
article

LONG-TERM OUTCOMES OF DEEP BRAIN STIMULATION IN PATIENTS WITH PARKINSON'S DISEASE

article en

Abstract

Deep Brain Stimulation (DBS) has established itself over the past two decades as an effective method for comprehensive treatment of Parkinson's disease when conservative therapy proves ineffective or insufficiently effective. The method is based on the implantation of electrodes into specific brain structures (predominantly the subthalamic nucleus, globus pallidus, or ventral intermediate nucleus of the thalamus) with subsequent activation through a subcutaneously implanted neurostimulator. Electrical stimulation modulates pathological neuronal activity in the basal ganglia, which leads to a reduction in the main motor symptoms of the disease and allows for a significant decrease in the dosage of antiparkinsonian medications.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 40%
Neurological disorders and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.